ArticleAmerican journal of ophthalmology2026
Modeling of Lowe Patient-Derived Induced Pluripotent Stem Cells Into Trabecular Meshwork.
Article in American journal of ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
purposeCongenital glaucoma is the leading cause of vision loss in patients with Lowe syndrome (LS), a rare X-linked disease caused by mutations in the OCRL gene. OCRL encodes an inositol polyphosphate 5-phosphatase. Despite significant research efforts, the pathogenesis of glaucoma caused by OCRL deficiency remains unclear, partly due to the inaccessibility of patient-derived ocular cells.
designThe study design is a comparative cell-based study focused on the functional characterization of induced human trabecular meshwork (iHTM) cell lines.
methodsTwo induced LS pluripotent stem cell (iPSC) lines, previously isolated and generated from an LS patient family, were differentiated into trabecular meshwork cells. LS100 is an affected LS patient; LS200 is an unaffected healthy sibling. Patient-based trabecular meshwork (iHTM) cell models were generated. Both stem cell and trabecular meshwork markers were evaluated by both immunoblot as well as immunostaining analysis.
resultsInduced trabecular meshwork cells expressed TM cell markers such as collagen IV, accompanied by the loss of pluripotency markers like OCT4. TM-like responses upon dexamethasone challenge included increased cross-linked actin network formation. The phagocytic function of TM cells was demonstrated by fluorescent labeling phagocytosis assay. Immunostaining revealed that compared to LS200-iHTM, LS100-iHTM had shortened primary cilia. This defect was further supported by reduced Gli1 protein expression in LS100-iHTM. Immunostaining of LAMP1, a lysosome marker, showed greater perinuclear lysosome clustering in LS100-iHTM than LS200-iHTM, indicating potentially dysfunctional nutrient sensing in the patient-derived iHTM cells.
conclusionsWe established two iHTM cell lines derived from iPSCs of an LS patient and his healthy sibling. Functional characterization of both cell lines showed that OCRL deficiency in LS altered downstream pathways related to phagocytosis, primary ciliogenesis, and lysosome positioning. iHTM cells function like TM cells and retain LS-associated defects, highlighting their potential as in vitro models for future mechanistic and therapeutic studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.